Antiviral Drugs Market Worth USD 44.2 billion by 2026, at 3.2% CAGR; Rising Prevalence of HIV to Fuel Growth: Fortune Business Insights™

Key Companies Covered in the Antiviral Drugs Market Research Report are Abbvie, Inc., Novartis AG, Gilead Sciences, Mylan N.V., GlaxoSmithKline, Merck & Co., Inc., Janssen, Pharmaceuticals, Inc., Bristol-Myers Squibb Company and other key market players.

Pune, Feb. 20, 2020 (GLOBE NEWSWIRE) -- The global Antiviral Drugs Market is set to gain impetus from the improvements in research collaborations of industry giants to develop state-of-the-art therapeutics. Besides, the increasing prevalence of viral diseases would impact the market positively. Fortune Business Insights™ published this information in a recent study, titled, “Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026.” The study further mentions that the Antiviral Drugs Market size is projected to reach USD 44.2 billion by 2026, thereby exhibiting a CAGR of 3.2% during the forecast period. However, it stood at USD 36.1 billion in 2018.

For more information in the analysis of this report, visit:

Highlights of the Report

  • Extensive analysis of the Antiviral Drugs Market trends, growth drivers, hindrances, opportunities, and challenges.
  • Profiles of the key organizations and their business strategies.
  • Quantitative analysis from 2019 to 2026 to help the stakeholders in capitalizing on the existing opportunities.
  • Detailed information about every possible segment present in the market.

High Demand for Targeted & Specific Treatment Regimen to Boost Growth

One of the most common forms of viral infection that is occurring across the world is HIV. The diagnosis rate of HIV is improving gradually owing to the refinement of surveillance by using biological and demographic data. The World Health Organization (WHO) stated that in the year 2018, approximately 37.9 million people were affected by HIV. However, around 770,000 people died of this disease. It proves that the rising cases of HIV is fueling the demand for specific and targeted treatment regimen. Apart from that, the rising prevalence of influenza and its efficient diagnosis are set to drive the Antiviral Drugs Market growth in the coming years.

Increasing Outburst of Viral Diseases to Favor Growth in Asia Pacific 

Geographically, the market is divided into the Middle East and Africa, North America, Europe, Asia Pacific, and Latin America. Out of these, North America held USD 13.9 billion Antiviral Drugs Market revenue in 2018. This growth is attributable to the presence of various key pharmaceutical companies in the U.S. Coupled with this, green signal by USFDA for the launch of effective and blockbuster therapies, as well as rising incidence of HIV in this country are set to augment growth in North America. Europe is also expected to grow remarkably on account of the presence of favorable reimbursement policies.

Request a Sample Copy of the Research Report:

Asia Pacific, on the other hand, is anticipated to exhibit a high CAGR during the forthcoming period. This growth is attributable to the frequent outbursts of viral diseases, namely, swine flu, dengue, and Ebola in the emerging economies. Besides, enhanced pharmaceutical industry in countries, such as Japan and India, as well as an established supply network are likely to accelerate growth in this region. In Latin America, the governments of Mexico and Brazil are taking persistent initiatives to manage viral infections. In addition to this, the increasing number of generic pharmaceutical companies present in this region would contribute to the growth.

Study by FSU Aid in Battling HIV & Hepatitis B; Gilead Submits sNDA Application to FDA

Key enterprises present in the market are constantly striving to bring about new treatment options for the patients suffering from viral infections. They are aiming to gain the maximum Antiviral Drugs Market share by bagging FDA approvals to broaden product portfolio. Educational institutions are also actively participating in conducting studies to discover new drugs. Below are two of the latest industry developments:

  • January 2020: The researchers of Florida State University (FSU) are set to open new doors for innovative treatment options for more than 36 million HIV-infected people across the globe. The new treatment options would also help treating the chronically ill patients with hepatitis B. For the first time, their work has established the mechanism accountable for how two antiviral drugs inhibit viruses.
  • April 2019: Gilead Sciences, Inc., a biotechnology company that researches, develops, and commercializes drugs, based in California, announced its submission of a supplemental New Drug Application (sNDA) to the FDA. It was done for its emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets called Descovy for pre-exposure prophylaxis (PrEP) to prevent sexually transmitted HIV-1 infection in those who are at risk.

Fortune Business Insights™ profiles some of the most prominent companies operating in the Antiviral Drugs Market. They are as follows:

  • Abbvie, Inc.
  • Novartis AG
  • Gilead Sciences
  • Mylan N.V.
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Janssen Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Other key market players

Have Any Query? Ask Our Experts:

Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Key Industry Trends
    • Recent industry developments such as mergers & acquisitions
    • regulatory and reimbursement scenario for key countries
    • Prevalence of Key viral diseases, in major countries, 2018
    • New Product Launches
  • Global Antiviral Drugs Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Disease Indication
      • Hepatitis
      • Human Immunodeficiency Virus (HIV)
      • Influenza
      • Others
    • Market Analysis, Insights and Forecast – By Drug Class
      • Integrase Inhibitors
      • Polymerase Inhibitors
      • Protease Inhibitors
      • Combination Drugs
      • Reverse Transcriptase Inhibitors
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacy
      • Retail Pharmacy
      • Online Channel
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa

TOC Continued….!

Request for Customization:

Have a Look at Related Reports:

Hiv/Aids Drugs Market Size, Share and Global Trend By Drug Class (Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Inhibitors, Combination HIV Medicines, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Geography Forecast Till 2026

Hepatitis C Drug Market Size, Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026

Vaccines Market Size, Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026

Influenza Vaccine Market Size, Share & Industry Analysis, By Type (Inactivated and Live Attenuated), By Valency (Quadrivalent and Trivalent), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026

Orphan Drugs Market Size, Share and Industry Analysis By Therapy Area (Oncology, Blood, CNS, Endocrine, Cardiovascular, Respiratory, Immunomodulatory), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales) and Regional Forecast, 2018 – 2025

Diabetes Drugs Market Size, Share and Industry Analysis By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Regional Forecast 2019 – 2026

Hemophilia Drugs Market Size, Share and Industry Analysis By Disease Indication (Hemophilia A, B & C), By Therapy Type (Recombinant Therapy, Plasma Therapy & Others), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast 2018-2025

Veterinary Drugs Market Size, Share and Industry Analysis by Product (Anti-infectives, Anti-inflammatory, Parasiticides, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral,Topical), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others,) and Regional Forecast, 2018 – 2025

Antipsychotic Drugs Market Size, Share and Industry Analysis, By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Others), By Therapeutic Class (First Generation, Second Generation, Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast 2019-2026

Cardiovascular Drugs Market Size, Share & Industry Analysis, By Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), By Disease Indication (Hypertension, Hyperlipidemia, Coronary Artery Disease, Arrhythmia, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019 -2026

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Fortune Business Insights™
LinkedIn | Twitter | Blogs

Press Release: